NCT06585592已完成不适用
Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated Ophthalmopathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 500
- 主要终点
- Percentage of participants with overall response
研究概览
简要总结
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.
The aim of this clinical study is to:
- Found characteristic changes from baseline to the end of treatment.
- Identify characteristic changes associated with treatment response.
- Construct a multimodal and multiparameter prediction model by characteristic changes.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •According to the Bartley criteria，diagnosed TAO from 2017/1/1 to 2024/3/31
- •Moderate to severe patients defined by EUGOGO
- •CAS ≥4 (on the 7-item scale) for the study eye
- •Completed orbital MRI at our hospital
- •Received complete medical treatment and completed assessment at our hospital
排除标准
- •Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
- •History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to < 1 g of methylprednisolone for the treatment of TAO.
- •Any major illness/condition or evidence of an unstable clinical condition that, in the investigators judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
- •Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participants participation in the study
- •Pregnant or lactating
- •Any other condition that,would impair the ability of the participant to undergo orbital MRI
结局指标
主要结局
Percentage of participants with overall response
时间窗: 104 weeks after the end of treatment
Overall response
次要结局
- Incidence and characterization of nonserious treatment emergent adverse events (TEAEs) during the treament(during the treament)
- Change of Serum TRAb from baseline(52 weeks after the end of treatment)
- Change of Serum T3,T4 level from baseline(52 weeks after the end of treatment)
- Change of Serum lipid parameter(52 weeks after the end of treatment)
- Change of Serum TSH level from baseline(52 weeks after the end of treatment)
- Change of Serum FT3, FT4 level from baseline(104 weeks after the end of treatment)
研究者
LiTuo
Deputy Director
Shanghai Changzheng Hospital
相似试验
招募中
不适用
Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated OphthalmopathyThyroid Associated OphthalmopathyNCT06590220Shanghai Changzheng Hospital150
Unknown
不适用
The Therapeutic Effect of Dysthyroid Optic NeuropathyThyroid Eye DiseaseNCT04096612Sun Yat-sen University20
Unknown
4 期
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior TrialThyroid Associated OphthalmopathyNCT03107078Jie Shen200
Unknown
不适用
Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT ScanThyroid Related OrbitopathyNCT00646295Sheba Medical Center30
已完成
4 期
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone InjectionsThyroid-associated OphthalmopathyNCT01599273Yonsei University50